Digestive Diseases and Sciences

, Volume 41, Issue 9, pp 1733–1740 | Cite as

Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis

  • Albert J. Czaja
  • Karin D. Pfeifer
  • Richard H. Decker
  • Ana S. Vallari
Liver: Infectious, Inflammatory, And Metabolic Disorders

Abstract

Antibodies to asialoglycoprotein receptor have diagnostic specificity for autoimmune hepatitis, but it is uncertain if they are complementary or redundant markers of the disease. Our aims were to assess their frequency and significance in type 1 autoimmune hepatitis and determine their contribution to the evaluation of these patients. Sear from 54 well-characterized patients were evaluated for antibodies to asialoglycoprotein receptor by a radioimmunofiltration assay based on rabbit-derived protein. Forty-four patients (82%) were seropositive. Seropositive patients were distinguished from seronegative counterparts by having higher serum gamma globulin (3.7±0.2 g/dl vs 2.3±0.3 g/dl,P=0.0007) and immunoglobulin G levels (3707±179 mg/dl vs 2203±263 mg/dl,P=0.0005) at presentation and a greater frequency of relapse after drug withdrawal (88% vs 33%,P=0.01). Seropositivity for smooth muscle and/or antinuclear antibodies did not define treatment outcomes and antinuclear antibodies occurred less frequently than the other markers. Concurrent testing for antibodies to asialoglycoprotein receptor and smooth muscle identified all patients. We conclude that antibodies to asialoglycoprotein receptor are common in type 1 autoimmune hepatitis and they identify patients with a high frequency of relapse after corticosteroid withdrawal. Concurrent testing for these antibodies and smooth muscle antibodies has the same diagnostic sensitivity as testing for antinuclear and smooth muscle antibodies but a greater prognostic implication.

Key words

asialoglycoprotein receptor autoantibodies autoimmune hepatitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Czaja AJ: Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 4:1–12, 1984PubMedGoogle Scholar
  2. 2.
    Czaja AJ: Autoimmune hepatitis: Evolving concepts and treatment strategies. Dig Dis Sci 40:435–456, 1995PubMedGoogle Scholar
  3. 3.
    Johnson PJ, McFarlane IG, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, Chapman RW, Czaja AJ, Desmet V, Eddleston ALWF, Gerber MA, Hoofnagle JH, Kakumu S, MacSween RNM, Maddrey WC, Manns MP, Meyer zum Buschenfelde K-H, Mieli-Vergani G, Portmann BC, Reed WD, Schalm SW, Scheuer PJ, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M: Meeting report. International Autoimmune Hepatitis Group. Hepatology 18:998–1005, 1993PubMedGoogle Scholar
  4. 4.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513–1520, 1994PubMedGoogle Scholar
  5. 5.
    International Working Party: Terminology of chronic hepatitis. Am J Gastroenterol 90:181–189, 1995Google Scholar
  6. 6.
    Czaja AJ: Autoimmune chronic active hepatitis-a specific entity? The negative argument. J Gastro-Hepatol 5:343–351, 1990Google Scholar
  7. 7.
    Czaja AJ: Chronic active hepatitis: The challenge for a new nomenclature. Ann Intern Med 119:510–517, 1993PubMedGoogle Scholar
  8. 8.
    Czaja AJ, Manns MP: The validity and importance of subtypes of autoimmune hepatitis: A point of view. Am J Gastroenterol 90:1206–1211, 1995PubMedGoogle Scholar
  9. 9.
    Homberg J-C, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy V-G, Grippon P, Opolon P, Bernuau J, Benhamou J-P, Alagille D: Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of “autoimmune” hepatitis. Hepatology 7:1333–1339, 1987PubMedGoogle Scholar
  10. 10.
    Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde K-H: Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1:292–294, 1987PubMedGoogle Scholar
  11. 11.
    Stechemesser E, Klein R, Berg PA: Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 18:1–9, 1993PubMedGoogle Scholar
  12. 12.
    Czaja AJ, Carpenter HA, Manns MP: Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 105:1522–1528, 1993PubMedGoogle Scholar
  13. 13.
    Czaja AJ, Manns MP, Homburger HA: Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103:1290–1295, 1992PubMedGoogle Scholar
  14. 14.
    Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF: Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 85:713–717, 1983PubMedGoogle Scholar
  15. 15.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 108:157–164, 1995PubMedGoogle Scholar
  16. 16.
    Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, Bonkovsky HL: High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 21:613–619, 1995PubMedGoogle Scholar
  17. 17.
    Tan EM, Chan EKL, Sullivan KF, Rubin RL: Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 47:121–141, 1988PubMedGoogle Scholar
  18. 18.
    Tan EM: Antinuclear antibodies. Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93–151, 1989PubMedGoogle Scholar
  19. 19.
    Toh B-H: Smooth muscle autoantibody and autoantigens. Clin Exp Immunol 38:621–628, 1979PubMedGoogle Scholar
  20. 20.
    Czaja AJ, Nishioka M, Morshed SA, Hachiya T: Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 107:200–207, 1994PubMedGoogle Scholar
  21. 21.
    Czaja AJ, Ming C, Shirai M, Nishioka M: Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol 23:32–38, 1995Google Scholar
  22. 22.
    Dighiero G, Lymberi P, Monot C, Abuaf N: Sera with high levels of anti-smooth muscle and anti-mitochondrial antibodies frequently bind to cytoskeletal proteins. Clin Exp Immunol 82:52–56, 1990PubMedGoogle Scholar
  23. 23.
    Treichel U, Poralla T, Hess G, Manns M, Meyer zum Buschenfelde K-H: Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology 11:606–612, 1990PubMedGoogle Scholar
  24. 24.
    Poralla T, Treichel U, Lohr H, Fleischer B: The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 11:215–222, 1991PubMedGoogle Scholar
  25. 25.
    Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Buschenfelde K-H, Poralla T: Autoantibodies against the human asialoglycoprotein receptor: Effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol 19:55–63, 1993PubMedGoogle Scholar
  26. 26.
    Treichel U, McFarlane BM, Seki T, Krawitt EL, Alessi N, Stickel F, McFarlane IG, Kiyosawa K, Furuta S, Freni MA, Gerken G, Meyer zum Buschenfelde K-H: Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 107:799–804, 1994PubMedGoogle Scholar
  27. 27.
    McFarlane BM, Sipos J, Gove CD, McFarlane IG, Williams R: Antibodies against the hepatic asialoglycoprotein receptor perfused in situ perferentially attach to periportal liver cell in the rat. Hepatology 11:408–415, 1990PubMedGoogle Scholar
  28. 28.
    Vento S, Hegarty JE, Bottazzo G, Macchia E, Williams R, Eddleston ALWF: Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet 1:1200–1204, 1984PubMedGoogle Scholar
  29. 29.
    O'Brien CJ, Vento S, Donaldson PT, McSorley CG, McFarlane IG, Williams R, Eddleston ALWF: Cell-mediated immunity and suppressor-T-cell defects to liver-derived antigens in families of patients with autoimmune chronic active hepatitis. Lancet 1:350–353, 1986PubMedGoogle Scholar
  30. 30.
    Vento S, O'Brien CJ, McFarlane IG, Williams R, Eddleston ALWF: T-cell inducers of suppressor lymphocytes control liver-directed autoreactivity. Lancet 1:886–888, 1987PubMedGoogle Scholar
  31. 31.
    Lohr H, Treichel U, Poralla T, Manns M, Meyer zum Buschenfelde K-H, Fleischer B: The human hepatic asialoglycoprotein receptor is a target for liver-infiltrating T cells in autoimmune chronic active hepatitis and primary biliary cirrhosis. Hepatology 12:1314–1320, 1990PubMedGoogle Scholar
  32. 32.
    Lohr H, Treichel U, Poralla T, Manns M, Meyer zum Buschenfelde K-H, Fleischer B: Liver-infiltrating T helper cells stimulate the production of autoantibodies against the human asialoglycoprotein receptor in autoimmune chronic active hepatitis in vitro. Clin Exp Immunol 88:45–49, 1992PubMedGoogle Scholar
  33. 33.
    DiMagno EP, Corle D, O'Brien JF, Masnyk IJ, Go VLW, Aamodt R: Effect of long-term freezer storage, thawing, and refreezing on selected constituents of serum. Mayo Clin Proc 64:1226–1234, 1989PubMedGoogle Scholar
  34. 34.
    Czaja AJ, Carpenter HA: Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824–1832, 1993PubMedGoogle Scholar
  35. 35.
    Czaja AJ: Autoimmune hepatitis: current therapeutic concepts. Clin Immunother 1:413–429, 1994Google Scholar
  36. 36.
    McFarlane BM, McSorley CG, McFarlane IG, Williams R: A radioimmunoassay for detection of circulating antibodies reacting with the hepatic asialoglycoprotein receptor protein. J Immunol Methods 77:219–228, 1985PubMedGoogle Scholar
  37. 37.
    McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R: Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 2:954–956, 1984PubMedGoogle Scholar
  38. 38.
    McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R: Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol 55:347–354, 1984PubMedGoogle Scholar
  39. 39.
    McFarlane BM, McSorley CG, Vergani D, McFarlane IG, Williams R: Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver diseases. J Hepatol 3:196–205, 1986PubMedGoogle Scholar
  40. 40.
    McFarlane IG, Smith HM, Johnson PJ, Bray GP, Vergani D, Williams R: Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet 335:754–757, 1990PubMedGoogle Scholar
  41. 41.
    Esteban JI, Esteban R, Viladomiu L, Lopez-Talavera JC, Gonzalez A, Hernandez JM, Roget M, Vargas V, Guardia J, Houghton M, Choo Q-L, Kuo G: Hepatitis C virus antibodies among risk groups in Spain. Lancet 2:294–297, 1989PubMedGoogle Scholar
  42. 42.
    Soloway RD, Summerskill WHJ, Baggenstoss AH, Schoenfield LJ: “Lupoid” hepatitis, a nonentity in the spectrum of chronic active liver disease. Gastroenterology 63:458–465, 1972PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Albert J. Czaja
    • 1
    • 2
  • Karin D. Pfeifer
    • 1
    • 2
  • Richard H. Decker
    • 1
    • 2
  • Ana S. Vallari
    • 1
    • 2
  1. 1.Mayo ClinicFrom the Division of Gastroenterology and Internal MedicineRochester
  2. 2.Abbott Laboratoriesthe Diagnostics DivisionNorth Chicago

Personalised recommendations